A comparative study of intravenous accelerated streptokinase dose regimen with conventional dose regimen for coronary thrombolysis

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Acute myocardial infarction (AMI) requires prompt restoration of coronary blood flow.
• Thrombolytic therapy, including streptokinase, is a key treatment for AMI.
• Optimizing thrombolytic regimens is crucial for improving patient outcomes.

Purpose of the Study:

• To compare the efficacy and safety of an accelerated streptokinase dose regimen versus a conventional regimen for coronary thrombolysis in AMI patients.
• To evaluate the patency rate and reperfusion success of the two streptokinase dosing strategies.

Main Methods:

• A randomized trial involving 104 patients with definite AMI within 12 hours of symptom onset.
• Patients received either accelerated (1.5 million units/30 min) or conventional (1.5 million units/60 min) intravenous streptokinase.
• Reperfusion was assessed by clinical evidence, with subgroup analysis for patients presenting within 6 hours.

Main Results:

• The accelerated regimen achieved a higher reperfusion rate (76.6%) compared to the conventional regimen (61.4%).
• This difference was statistically significant in patients treated within 6 hours of chest pain onset (87.9% vs. 67.4%, P < 0.05).
• Incidence of mild bleeding, allergic reactions, and hypotension was comparable between the groups.

Conclusions:

• The accelerated streptokinase dose regimen demonstrates improved reperfusion rates in AMI without a significant increase in adverse events.
• This faster thrombolytic approach holds promise for more effective treatment of acute myocardial infarction.
• Further extensive investigation into accelerated streptokinase therapy is recommended.